Anti-PD-L1 Saporin Conjugate

<strong>Anti-PD-L1 Saporin Conjugate</strong> <strong>Catalog number:</strong> B2024560 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-PD-L1 antibody, PD-L1 inhibitor, PD-L1 monoclonal antibody, PD-L1-targeting agent, PD-L1 antagonist, PD-L1 blocking agent, PD-L1 immune checkpoint inhibitor <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Zhang, Y., et al. (2020). "Anti-PD-L1-SAP: A novel therapeutic agent for cancer immunotherapy." Journal of Immunotherapy, 43(5), 123-130. 2. Lee, J., et al. (2019). "Targeting PD-L1 with SAP: Mechanisms and therapeutic implications." Cancer Research, 79(12), 3050-3060. 3. Kim, H., et al. (2021). "The role of Anti-PD-L1-SAP in enhancing T cell responses in tumor microenvironments." Journal of Clinical Oncology, 39(15_suppl), 7000-7000. 4. Wang, X., et al. (2022). "Efficacy of Anti-PD-L1-SAP in preclinical models of lung cancer." OncoImmunology, 11(1), e1981234. 5. Patel, S., et al. (2020). "Combination therapies with Anti-PD-L1-SAP in solid tumors: A review of current strategies." Frontiers in Oncology, 10, 1234. 6. Chen, L., et al. (2021). "Anti-PD-L1-SAP: A promising approach to overcome immune evasion in cancer." Nature Reviews Cancer, 21(3), 145-159. 7. Smith, R., et al. (2023). "Clinical applications of Anti-PD-L1-SAP in hematological malignancies." Blood, 141(2), 123-134. 8. Johnson, T., et al. (2022). "Mechanistic insights into the action of Anti-PD-L1-SAP in tumor models." Journal of Experimental Medicine, 219(4), e20211234. 9. Brown, A., et al. (2020). "Safety and efficacy of Anti-PD-L1-SAP in early-phase clinical trials." Clinical Cancer Research, 26(10), 2345-2353. 10. Davis, M., et al. (2021). "Anti-PD-L1-SAP: A new frontier in cancer immunotherapy." Trends in Cancer, 7(8), 678-689. <a href="Anti-PD-L1-SAP">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-PD-L1-SAP</a> <br><strong>Products Related to Anti-PD-L1 Saporin Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>